These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34180007)

  • 1. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
    Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
    Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
    Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
    Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer.
    Low JL; Huang Y; Sooi K; Ang Y; Chan ZY; Spencer K; Jeyasekharan AD; Sundar R; Goh BC; Soo R; Yong WP
    Int J Cancer; 2021 Jul; 149(1):169-176. PubMed ID: 33634869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
    Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
    Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.
    Shijubou N; Sumi T; Yamada Y; Nakata H; Mori Y; Chiba H
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1893-1901. PubMed ID: 35397688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
    Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
    Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study.
    Murteira R; Borges FC; Mendes GP; Ramos C; Ramos A; Soares P; Furtado C; Miranda A; da Costa FA;
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1295-1302. PubMed ID: 32844487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
    Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
    Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
    Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
    Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
    Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
    Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.